Charles Schwab
VERV

Charles Schwab’s Verve Therapeutics VERV Stock Holding History

Charles Schwab’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-592,436
Closed -$6.65M – 3544
2025
Q2 		$6.65M Buy
592,436
+24,252
+4% +$138K ﹤0.01% 2206
2025
Q1 		$2.6M Sell
568,184
-2,534
-0.4% -$17K ﹤0.01% 2530
2024
Q4 		$3.22M Sell
570,718
-1,455
-0.3% -$8.21K ﹤0.01% 2528
2024
Q3 		$2.77M Buy
572,173
+126,110
+28% +$732K ﹤0.01% 2605
2024
Q2 		$2.18M Sell
446,063
-40,944
-8% -$257K ﹤0.01% 2683
2024
Q1 		$6.47M Buy
487,007
+117,337
+32% +$1.56M ﹤0.01% 2191
2023
Q4 		$5.15M Buy
369,670
+6,626
+2% +$82.1K ﹤0.01% 2301
2023
Q3 		$4.81M Buy
363,044
+27,605
+8% +$445K ﹤0.01% 2279
2023
Q2 		$6.29M Buy
335,439
+13,139
+4% +$219K ﹤0.01% 2136
2023
Q1 		$4.65M Buy
322,300
+1,723
+0.5% +$33.7K ﹤0.01% 2241
2022
Q4 		$6.2M Buy
320,577
+13,724
+4% +$364K ﹤0.01% 2107
2022
Q3 		$10.5M Buy
306,853
+161,963
+112% +$5.17M ﹤0.01% 1803
2022
Q2 		$2.21M Sell
144,890
-8,660
-6% -$134K ﹤0.01% 2542
2022
Q1 		$3.5M Buy
153,550
+48,824
+47% +$1.4M ﹤0.01% 2452
2021
Q4 		$3.86M Buy
104,726
+1,916
+2% +$80.5K ﹤0.01% 2476
2021
Q3 		$4.83M Buy
+102,810
New +$6.05M ﹤0.01% 2390

Other funds holding VERV

GCM
Greenland Capital Management New York $812M AUM 45.54% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Charles Schwab's VERV Position: Q3 2025 in Review

Charles Schwab sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 592,436 shares — an estimated $6.65M sold.

Charles Schwab first reported a position in VERV in Q3 2021 and held it in 16 quarters. The position peaked at $10.5M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Charles Schwab reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 592,436 Verve Therapeutics shares in Q3 2025, an estimated $6.65M.
  • Charles Schwab first reported a position in Verve Therapeutics in Q3 2021 and held it in 16 quarters.
  • Charles Schwab's Verve Therapeutics position peaked at $10.5M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.